Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1
Data
2010-04-15
Autores
Felicio, Andre C. 
Godeiro-Junior, Clecio
Shih, Ming C.
Borges, Vanderci
Silva, Sonia M. A.
Mostrar mais
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Despite its relatively high prevalence Parkinson's Disease (PD) is still misdiagnosed in approximately 25% of cases. in this study our aim was to evaluate patients with Clinically Unclear Parkinsonian Syndromes (CUPS) submitted to brain SPECT imaging using the technetium-99m labeled Dopamine Transporter (DAT) tracer TRODAT-1. We recruited 15 subjects with CUPS and matched them with 13 patients with probable PD and 13 healthy control subjects (HCS). A SPECT with TRODAT-1 was performed at the baseline evaluation and patients from the CUPS were followed-up for 2-years to ensure or not PD diagnosis (gold-standard). the mean +/- SD results from Right and Left striatum Binding Potential (BP) were, respectively, 1.08 +/- 0.20 and 1.04 +/- 0.16 in the HCS group, 0.47 +/- 0.16 and 0.53 +/- 0.17 in the PD group, and 0.68 +/- 0.11 and 0.84 +/- 0.17 in the CUPS group. the rate of disagreement between baseline SPECT in the CUPS group as compared to the gold standard diagnosis (clinical diagnosis of PD on follow-up) was of 20%. the sensitivity of the SPECT with TRODAT-1 was 100%, while specificity was 70%. in conclusion, our data provided further information about the role of the technetium-99m labeled tracer TRODAT-1 as a biomarker of DAT reduction that can also be used in the diagnosis of patients with CUPS. (C) 2010 Elsevier By. All rights reserved.
Descrição
Citação
Journal of the Neurological Sciences. Amsterdam: Elsevier B.V., v. 291, n. 1-2, p. 64-68, 2010.